Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: Xenetic Biosciences, Inc. (XBIO)
Filing Date: October 12, 2021
Reporting Period: Current Report (Event Date: October 12, 2021)
Business Focus: Development of XCART technology for B-cell malignancies.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses a specific transactional payment:
- One-time Payment: $40,000 paid to PJSC Pharmsynthez.
- Payment Allocation: $21,000 settled all outstanding compensation owed under the prior Work Order; $19,000 credited toward future out-of-pocket costs and expenses under new work orders.
Material Changes
On October 12, 2021, the Company amended its Master Service Agreement (MSA) with PJSC Pharmsynthez:
- Termination: The original Work Order (dated June 12, 2020) was terminated without penalty.
- New Agreement: A "Second Work Order" was executed simultaneously. Under this new arrangement, Pharmsynthez will provide services upon the Company's written request rather than under a fixed study scope.
- Operational Impact: No further services were performed under the original Work Order; future services are covered by the new flexible work order structure.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to file the full text of the MSA Amendment and Second Work Order as exhibits to its Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Risks and Uncertainties: Forward-looking statements are subject to risks including:
- Failure to realize the potential of XCART technology.
- Pharmsynthez's ability to perform obligations under the new agreement.
- Failure to reach agreements with third-party contract sites on favorable terms.
- General market factors, economic conditions, and the impact of the COVID-19 outbreak.
- Regulatory processes, manufacturing issues, and patent litigation.
Investor Verification Checklist
- Verify the full text of the MSA Amendment and Second Work Order when filed as exhibits to the 2021 Form 10-K.
- Confirm the status of the $19,000 credit and how it will be applied to future out-of-pocket costs.
- Monitor future filings for new work orders initiated under the flexible service model.
- Review the "Risk Factors" section of the most recent Form 10-K for detailed operational and regulatory risks.